News Releases

Interim data show sebetralstat enables early, effective treatment of hereditary angioedema (HAE) attacks in children with favorable safety and tolerability FRAMINGHAM, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 30, 2026-- KalVista Pharmaceuticals, Inc.

$49.1 million global net product revenue of EKTERLY ® (sebetralstat) for the eight months ended December 31, 2025 1,702 patient start forms received in the US from launch through end of February, reflecting continued rapid adoption of first and only oral on-demand treatment for hereditary

New interim data from the KONFIDENT-KID trial evaluating sebetralstat in children aged 2-11 accepted for late-breaking oral presentation FRAMINGHAM, Mass. & SALISBURY, England--( BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that five abstracts, including one

FRAMINGHAM, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 18, 2026-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Wednesday, March 25, 2026, at 8:30 a.m. ET to review the Company’s eight months fiscal year 2025 financial results and provide a

FRAMINGHAM, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 4, 2026-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Compensation Committee of KalVista’s Board of Directors granted one newly-hired employee inducement options to purchase an aggregate of 6,750 shares of

Presentations highlight patient preference for sebetralstat, early treatment as the strongest driver of response, and sustained effectiveness with use in clinical trials FRAMINGHAM, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 2, 2026-- KalVista Pharmaceuticals, Inc.

FRAMINGHAM, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 25, 2026-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at each of the following upcoming investor conferences: TD Cowen 46 th Annual Healthcare Conference on

Guideline recommends ensuring on-demand treatment is available anytime, anywhere and prioritizes early intervention and rapid self-administration, reinforcing the unique value of EKTERLY FRAMINGHAM, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 18, 2026-- KalVista Pharmaceuticals, Inc.

FRAMINGHAM, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 12, 2026-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of three abstracts for presentation at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in

FRAMINGHAM, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 3, 2026-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista’s Board of Directors granted six newly-hired employees inducement options to purchase an aggregate of 96,750 shares of